The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant.
Christina
C
Justenhoven
Ofure
O
Obazee
Stefan
S
Winter
Fergus J
FJ
Couch
Janet E
JE
Olson
Per
P
Hall
Ulf
U
Hannelius
Jingmei
J
Li
Keith
K
Humphreys
Gianluca
G
Severi
Graham
G
Giles
Melissa
M
Southey
Laura
L
Baglietto
Peter A
PA
Fasching
Matthias W
MW
Beckmann
Arif B
AB
Ekici
Ute
U
Hamann
Christian
C
Baisch
Volker
V
Harth
Sylvia
S
Rabstein
Anne
A
Lotz
Beate
B
Pesch
Thomas
T
Brüning
Yon-Dschun
YD
Ko
Hiltrud
H
Brauch
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D065731:Cytochrome P-450 CYP2C19; D015914:Estrogen Replacement Therapy; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006801:Humans; D017698:Postmenopause; D012306:Risk
D012739:Gonadal Steroid Hormones; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19